Premarin Related Published Studies
Well-designed clinical trials related to Premarin (Conjugated Estrogens)
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. [2011.04.06]
Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. [2011.03.01]
Health outcomes after stopping conjugated equine estrogens among postmenopausal
women with prior hysterectomy: a randomized controlled trial. [2011]
Preventing osteoporosis with a tissue selective estrogen complex (TSEC)
containing bazedoxifene/conjugated estrogens (BZA/CE). [2011]
Long-term effects of conjugated equine estrogen therapies on domain-specific cognitive function: results from the Women's Health Initiative study of cognitive aging extension. [2010.07]
Cardiovascular and metabolic effects of medroxyprogesterone acetate versus conjugated equine estrogen after premenopausal hysterectomy with bilateral ovariectomy. [2010.05]
Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy. [2010.04]
A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women. [2010.03]
Cardiovascular and metabolic effects of medroxyprogesterone acetate versus
conjugated equine estrogen after premenopausal hysterectomy with bilateral
ovariectomy. [2010]
Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal
women with symptoms of vulvar/vaginal atrophy. [2010]
Conjugated equine estrogen influence on mammographic density in postmenopausal women in a substudy of the women's health initiative randomized trial. [2009.12.20]
Brain volumes, cognitive impairment, and conjugated equine estrogens. [2009.12]
Effects of conjugated equine estrogens on cognition and affect in postmenopausal women with prior hysterectomy. [2009.11]
Bazedoxifene effects on the reproductive tract in postmenopausal women at risk for osteoporosis. [2009.11]
Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. [2009.09]
Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. [2009.09]
Bazedoxifene/conjugated estrogens (BZA/CE): incidence of uterine bleeding in postmenopausal women. [2009.09]
Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. [2009.09]
Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women. [2009.08.20]
Efficacy and safety of low-dose regimens of conjugated estrogens cream administered vaginally. [2009.07]
Twice-weekly synthetic conjugated estrogens vaginal cream for the treatment of vaginal atrophy. [2009.07]
Conjugated oral versus transdermal estrogen replacement in girls with Turner syndrome: a pilot comparative study. [2009.06]
A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. [2009.03]
A randomized study of low-dose conjugated estrogens on sexual function and quality of life in postmenopausal women. [2008.11.20]
Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. [2008.10]
Conjugated Equine Estrogens and Colorectal Cancer Incidence and Survival: The Women's Health Initiative Randomized Clinical Trial. [2008.10]
Conjugated equine estrogen, raloxifene and arterial stiffness in postmenopausal women. [2008.10]
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. [2008.06.15]
A comparison of the short-term effects of oral conjugated equine estrogens versus transdermal estradiol on C-reactive protein, other serum markers of inflammation, and other hepatic proteins in naturally menopausal women. [2008.05]
Conjugated equine estrogen and risk of benign proliferative breast disease: a randomized controlled trial. [2008.04.16]
Effects of alcohol and cigarette smoking on change in serum estrone levels in postmenopausal women randomly assigned to fixed doses of conjugated equine estrogens with or without a progestin. [2008.03]
The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors. [2008]
Randomized, multicenter, double-blind, placebo-controlled trial to evaluate the efficacy and safety of synthetic conjugated estrogens B for the treatment of vulvovaginal atrophy in healthy postmenopausal women. [2007.11.28]
Body composition during treatment with conjugated estrogens with and without medroxyprogesterone acetate: analysis of the women's Health, Osteoporosis, Progestin, Estrogen (HOPE) trial. [2007.08]
Effect of three doses of conjugated estrogens/medroxyprogesterone acetate on biomarkers of bone turnover and cartilage degradation in postmenopausal women: The Pan-Asia Menopause (PAM) study. [2007.08]
Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. [2007.06]
Medroxyprogesterone and conjugated oestrogen are equivalent for hot flushes: a 1-year randomized double-blind trial following premenopausal ovariectomy. [2007.05]
Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. [2006.12]
Efficacy and tolerability of the Black cohosh (Actaea racemosa) ethanolic extract BNO 1055 on climacteric complaints: A double-blind, placebo- and conjugated estrogens-controlled study. [2006.11.01]
Effects of tibolone and continuous combined conjugated equine estrogen/medroxyprogesterone acetate on the endometrium and vaginal bleeding: results of the OPAL study. [2006.11]
Different effects of oral conjugated equine estrogens and transdermal estrogen on undercarboxylated osteocalcin concentration in postmenopausal women. [2006.07]
Effects of conjugated equine estrogen on risk of fractures and BMD in postmenopausal women with hysterectomy: results from the women's health initiative randomized trial. [2006.06]
Differential prevalence of quality-of-life categories (domains) in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia Menopause (PAM) study. [2006.06]
Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. [2006.05.23]
Clinical study comparing the effects of sequential hormone replacement therapy with oestradiol/dydrogesterone and conjugated equine oestrogen/norgestrel on lipids and symptoms. [2006.05]
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. [2006.04.12]
The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. [2006.03]
The effect of conjugated equine oestrogen on diabetes incidence: the Women's Health Initiative randomised trial. [2006.03]
Conjugated estrogen plus medroxyprogesterone does not impair blood rheological properties in hypertensive postmenopausal women. [2006.02.20]
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. [2006.02.13]
Randomized clinical trial comparing conjugated equine estrogens and isoflavones in postmenopausal women: a pilot study. [2006.01.10]
Conjugated estrogen/progestagen versus tibolone hormone replacement therapy in postmenopausal women: Effects on carbohydrate metabolism and serum sex hormone-binding globulin. [2006.01.10]
Prevalence of menopausal symptoms in different ethnic groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: the Pan-Asia menopause (PAM) study. [2005.11]
Effect of oral conjugated equine estrogen combined with medroxyprogesterone acetate on plasma homocysteine levels in postmenopausal women. [2005.10]
[Modification of C3 and C4 levels after the administration of conjugated estrogens plus medroxiprogesterone or raloxifene in postmenopausal women] [2005.10]
Effects of conjugated equine estrogen on health-related quality of life in postmenopausal women with hysterectomy: results from the Women's Health Initiative Randomized Clinical Trial. [2005.09.26]
Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. [2005.09.16]
Effect on sexual life--a comparison between tibolone and continuous combined conjugated equine estrogens and medroxyprogesterone acetate. [2005.04]
Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women. [2005.04]
Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women. [2005.03]
The effects of 17 beta-oestradiol plus dydrogesterone compared with conjugated equine oestrogens plus medroxyprogesterone acetate on lipids, apolipoproteins and lipoprotein(a). [2004.11.15]
Treatment of atrophic vaginitis with topical conjugated equine estrogens in postmenopausal Asian women. [2004.09]
Effects of conjugated equine estrogen vs. raloxifene on serum insulin-like growth factor-i and insulin-like growth factor binding protein-3: a 2-year, double-blind, placebo-controlled study. [2004.08]
Effect of continuous administration of conjugated estrogen plus medroxyprogesterone acetate (Premelle) in postmenopausal women in Taiwan. [2004.07]
Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study. [2004.07]
Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. [2004.06.23]
Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. [2004.06.23]
Effects of continuous combined conjugated estrogen/medroxyprogesterone acetate and 17beta-estadiol/norethisterone acetate on lipids and lipoproteins. [2004.06.15]
Lipoprotein compositional changes with combination hormone therapy (conjugated estrogen and medroxyprogesterone) in African American women. [2004.05]
Body mass index does not influence response to treatment, nor does body weight change with lower doses of conjugated estrogens and medroxyprogesterone acetate in early postmenopausal women. [2004.05]
A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women. [2004.04.26]
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. [2004.04.14]
Positive effects of conjugated equine estrogen on triglyceride metabolism in oophorectomized women based on a stratification analysis of pretreatment values. [2004.04]
Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women. [2004.03]
Effect of lower dosage of oral conjugated equine estrogen on inflammatory markers and endothelial function in healthy postmenopausal women. [2004.03]
Conjugated estrogens as adjuvant therapy in the treatment of acute schizophrenia: a double-blind study. [2004.02.01]
Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens. [2004.02]
Low-dose (0.3 mg) synthetic conjugated estrogens A is effective for managing atrophic vaginitis. [2004.01.20]
Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate: two-year substudy results. [2003.11]
Effect of lower dose of oral conjugated equine estrogen on size and oxidative susceptibility of low-density lipoprotein particles in postmenopausal women. [2003.08.19]
Acute administration of conjugated equine oestrogen does not improve exercise-induced myocardial ischaemia in men with coronary artery disease. [2003.05]
A comparison of two different dosages of conjugated equine estrogen in continuous combined hormone replacement therapy with progestin. [2003.04]
The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. [2003.03.14]
Effect of raloxifene on the response to conjugated estrogen vaginal cream or nonhormonal moisturizers in postmenopausal vaginal atrophy. [2003.02]
Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. [2003.01]
Bleeding patterns in peri and postmenopausal women taking a continuous combined regimen of estradiol with norethisterone acetate or a conventional sequential regimen of conjugated equine estrogens with medrogestone. [2002.12.10]
Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women. [2002.12.04]
Effect of transdermal estradiol and oral conjugated estrogen on C-reactive protein in retinoid-placebo trial in healthy women. [2002.09.03]
Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. [2002.05.22]
[Comparative study on two different dosages of conjugated equine estrogen continuously combined with medroxyprogesterone in prevention of postmenopausal osteoporosis] [2002.05]
A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. [2002.03]
Evaluation of single- and multiple-dose pharmacokinetics of synthetic conjugated estrogens, A (Cenestin) tablets: a slow-release estrogen replacement product. [2002.03]
Short-term effects of new synthetic conjugated estrogens on biochemical markers of bone turnover. [2002.03]
Effects of low-dose continuous combined conjugated estrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women. [2001.11]
The effect of estradiol vaginal tablet and conjugated estrogen cream on urogenital symptoms in postmenopausal women: a comparative study. [2001.10]
Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens. [2001.09]
Endometrial effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate. [2001.07]
Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. [2001.07]
Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. [2001.06]
Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. [2001.06]
Bleeding patterns in postmenopausal women using continuous combination hormone replacement therapy with conjugated estrogen and medroxyprogesterone acetate or with 17beta-estradiol and norethindrone acetate. [2001.05]
|
